“This quarter marks a turning point in the evolution of MiNK. Our platform is demonstrating the power of iNKT cells to transform immune responses in both cancer and inflammatory diseases,” said Jennifer Buell, Ph.D., President and Chief Executive Officer of MiNK Therapeutics (INKT). “With late-stage strategic discussions underway across oncology, immunology, and next-generation engineered cell therapies, MiNK is positioned to unlock the full value of our technology. These partnerships-alongside our clinical advances and expanded access to non-dilutive capital-will allow us to deliver off-the-shelf iNKT therapies to patients with urgency, focus, and scale.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INKT:
- INKT Upcoming Earnings Report: What to Expect?
- MiNK Therapeutics Reports 2024 Progress and Financials
- MiNK Therapeutics’ Earnings Call Highlights Strategic Gains
- Buy Rating Affirmed for MiNK Therapeutics Amid Promising Clinical Developments and Strategic Expansion
- Promising Clinical Data and Strategic Initiatives Drive Buy Rating for MiNK Therapeutics